Mechanisms Driving the Immunoregulatory Function of Cancer Cells

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2023 Jan 30

PMID 36717668

Authors

Antoinette van Weverwijk

Karin E de Visser

Affiliations

Soon will be listed here.

Abstract

Tumours display an astonishing variation in the spatial distribution, composition and activation state of immune cells, which impacts their progression and response to immunotherapy. Shedding light on the mechanisms that govern the diversity and function of immune cells in the tumour microenvironment will pave the way for the development of more tailored immunomodulatory strategies for the benefit of patients with cancer. Cancer cells, by virtue of their paracrine and juxtacrine communication mechanisms, are key contributors to intertumour heterogeneity in immune contextures. In this Review, we discuss how cancer cell-intrinsic features, including (epi)genetic aberrations, signalling pathway deregulation and altered metabolism, play a key role in orchestrating the composition and functional state of the immune landscape, and influence the therapeutic benefit of immunomodulatory strategies. Moreover, we highlight how targeting cancer cell-intrinsic parameters or their downstream immunoregulatory pathways is a viable strategy to manipulate the tumour immune milieu in favour of antitumour immunity.

Citing Articles

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.

Vo M, Nguyen V, Tran V, Oh H, Jung S, Bae W Cancer Immunol Immunother. 2025; 74(4):143.

PMID: 40056167 PMC: 11890499. DOI: 10.1007/s00262-025-03997-2.

High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.

Fan P, Qi Z, Liu Z, Wang S, Wang Y, Kuai J Cell Death Dis. 2025; 16(1):152.

PMID: 40038236 PMC: 11880386. DOI: 10.1038/s41419-025-07471-w.

Erythroid progenitor cell-mediated spleen-tumor interaction deteriorates cancer immunity.

Wu Z, Deng W, Zhu S, Wang W, Wang S, Yang Q Proc Natl Acad Sci U S A. 2025; 122(9):e2417473122.

PMID: 40014568 PMC: 11892600. DOI: 10.1073/pnas.2417473122.

Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.

Verona F, Di Bella S, Schirano R, Manfredi C, Angeloro F, Bozzari G Front Immunol. 2025; 16:1529847.

PMID: 39981232 PMC: 11839637. DOI: 10.3389/fimmu.2025.1529847.

Breast cancer: pathogenesis and treatments.

Xiong X, Zheng L, Ding Y, Chen Y, Cai Y, Wang L Signal Transduct Target Ther. 2025; 10(1):49.

PMID: 39966355 PMC: 11836418. DOI: 10.1038/s41392-024-02108-4.

References

Anderson N, Simon M . The tumor microenvironment. Curr Biol. 2020; 30(16):R921-R925. PMC: 8194051. DOI: 10.1016/j.cub.2020.06.081. View

Garner H, de Visser K . Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020; 20(8):483-497. DOI: 10.1038/s41577-019-0271-z. View

Jhunjhunwala S, Hammer C, Delamarre L . Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021; 21(5):298-312. DOI: 10.1038/s41568-021-00339-z. View

He X, Xu C . Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020; 30(8):660-669. PMC: 7395714. DOI: 10.1038/s41422-020-0343-4. View

Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L . Evolution of Metastases in Space and Time under Immune Selection. Cell. 2018; 175(3):751-765.e16. DOI: 10.1016/j.cell.2018.09.018. View

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View

Palucka A, Coussens L . The Basis of Oncoimmunology. Cell. 2016; 164(6):1233-1247. PMC: 4788788. DOI: 10.1016/j.cell.2016.01.049. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19):1789-1801. DOI: 10.1056/NEJMoa1802357. View

11.

Robert C, Ribas A, Hamid O, Daud A, Wolchok J, Joshua A . Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2017; 36(17):1668-1674. DOI: 10.1200/JCO.2017.75.6270. View

12.

Bejarano L, Jordao M, Joyce J . Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021; 11(4):933-959. DOI: 10.1158/2159-8290.CD-20-1808. View

13.

Davis-Marcisak E, Deshpande A, Stein-OBrien G, Ho W, Laheru D, Jaffee E . From bench to bedside: Single-cell analysis for cancer immunotherapy. Cancer Cell. 2021; 39(8):1062-1080. PMC: 8406623. DOI: 10.1016/j.ccell.2021.07.004. View

14.

Kim N, Kim H, Lee K, Hong Y, Cho J, Choi J . Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020; 11(1):2285. PMC: 7210975. DOI: 10.1038/s41467-020-16164-1. View

15.

Nieto P, Elosua-Bayes M, Trincado J, Marchese D, Massoni-Badosa R, Salvany M . A single-cell tumor immune atlas for precision oncology. Genome Res. 2021; 31(10):1913-1926. PMC: 8494216. DOI: 10.1101/gr.273300.120. View

16.

Wu S, Al-Eryani G, Roden D, Junankar S, Harvey K, Andersson A . A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021; 53(9):1334-1347. PMC: 9044823. DOI: 10.1038/s41588-021-00911-1. View

17.

Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y . Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021; 39(12):1578-1593.e8. DOI: 10.1016/j.ccell.2021.09.010. View

18.

Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue M . Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin Cancer Res. 2019; 25(16):5002-5014. DOI: 10.1158/1078-0432.CCR-18-3524. View

19.

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

20.

Sanchez-Vega F, Mina M, Armenia J, Chatila W, Luna A, La K . Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018; 173(2):321-337.e10. PMC: 6070353. DOI: 10.1016/j.cell.2018.03.035. View